In Re: Taxotere (Docetaxel) Products Liability Litigation
2:16-md-02740
E.D. La.Apr 30, 2025Background
- Plaintiffs, cancer patients, sued pharmaceutical manufacturers Accord Healthcare and Hospira, claiming that the chemotherapy drug docetaxel (Taxotere) caused permanent hair loss (PCIA) and that the companies failed to provide adequate warnings.
- After Sanofi’s Taxotere patent expired, Accord and Hospira received FDA approval to sell their own docetaxel versions using an abbreviated approval pathway based on Sanofi’s reference drug data.
- The plaintiffs’ state law claims center on allegations that defendants did not update their drug labels to warn of the risk of permanent alopecia, even as reports and studies on this risk became available.
- Accord and Hospira moved for summary judgment, arguing these state law claims were preempted by federal law, as changes to labels require “newly acquired information” under FDA regulations, which they claimed was absent.
- The district court originally denied summary judgment, but the Fifth Circuit vacated and remanded, clarifying the standards and burden regarding what qualifies as “newly acquired information.”
- Upon remand and further briefing, the district court found the relevant post-approval study (the Bertrand Abstract) did not sufficiently establish new or greater risk of permanent alopecia and thus granted summary judgment to the defendants.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether defendants could have updated labels under the CBE regulation | Plaintiffs claim post-approval studies show increased risk justifying a warning | Defendants argue no "newly acquired information" present | Court: No new info per FDA standard; defendants could not unilaterally change labels; claims are preempted |
| If the Bertrand Abstract is “newly acquired information” | Plaintiffs: Bertrand shows 33% incidence of permanent alopecia | Defendants: Bertrand unclear/definitions inconsistent | Court: Study’s definitions too vague; cannot reliably show increased risk compared to pre-approval baseline |
| Preemption of failure-to-warn state law claims by federal regulations | Plaintiffs: Federal regulations permit label changes with new data | Defendants: Lacked new data; impossible to comply with both | Court: Federal law preempts state claims absent newly acquired info justifying label change |
| Incidence rate calculation inclusions (minimal, moderate, severe cases) | Plaintiffs: Minimal cases should count as injury under legal/medical definition | Defendants: Minimal cases not clearly defined or connected | Court: Insufficient clarity on “minimal”; cannot include in incidence rate; summary judgment for defendants |
Key Cases Cited
- Wyeth v. Levine, 555 U.S. 555 (Supreme Court) (addressed impossibility preemption and when federal drug labeling law preempts state law claims)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (Supreme Court) (held that federal drug labeling law can preempt state failure-to-warn claims when it is impossible for manufacturers to comply with both)
- Merck Sharp & Dohme Corp. v. Albrecht, 587 U.S. 299 (Supreme Court) (clarified standards for FDA preemption of state drug labeling lawsuits)
- Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (Supreme Court) (stated the summary judgment standard)
- Celotex Corp. v. Catrett, 477 U.S. 317 (Supreme Court) (addressed parties’ burdens on summary judgment motions)
- Hickey v. Hospira, 102 F.4th 748 (5th Cir. 2024) (appellate ruling setting standards for what constitutes “newly acquired information” necessary for label changes and summary judgment in this case)